CCM
SUPN icon

Cupps Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Cupps Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-17,895
Closed -$251K – 194
2015
Q3 		$251K Buy
+17,895
New +$333K 0.03% 135

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cupps Capital Management's SUPN Position: Q4 2015 in Review

Cupps Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2015, closing a stake of 17,895 shares — an estimated $251K sold.

Cupps Capital Management first reported a position in SUPN in Q3 2015 and held it in 1 quarter. The position peaked at $251K in Q3 2015. 209 funds tracked by Wall St. Rank hold SUPN as of Q4 2015.

  • Cupps Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Cupps Capital Management sold 17,895 Supernus Pharmaceuticals shares in Q4 2015, an estimated $251K.
  • Cupps Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Cupps Capital Management's Supernus Pharmaceuticals position peaked at $251K in Q3 2015.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2015.

Based on Cupps Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.